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Abstract:  
Objective: To compare the effects of home non-invasive ventilation with oxygen therapy versus oxygen 
Therapy alone on patients of acute exacerbation of COPD 
    Study design:  A Randomized Controlled Trial. 
Place and Duration of Study:  Department of Pulmonology Nishtar Hospital Multan from April 2016 to march 
2018. 
Methodology: A total of 194 patients were divided into two groups of 100 and 94. There were 100 patients who 
were randomized to home oxygen alone. The number of patients who were given oxygen therapy with non 
invasive ventilation was 94. The non invasive ventilation was applied according to preference of patients by 
using nasal or total face masks. To increase the oxygen level to 60 mmHg, oxygen therapy was started at the 
minimum flow rate in both groups. The patients who were on oxygen therapy alone were instructed to undergo at 
least 15 hours of oxygen therapy daily. For the patients of other group, a minimum of 6 hours nightly use of 
ventilator was instructed. 
Results:  Ninety four patients were put on oxygen therapy combined with non-invasive ventilation and 100 
patients were put on just oxygen therapy. Both the groups were comparable in all baseline variables. After one 
year follow up, there was significant improvement in PaCO2, PaO2, St. George Respiratory Questionnaire 
summary score and Severe Respiratory Insufficiency Questionnaire summary score at most of the occasions (p-
value <0.001 for all at 3 months; .060, .013, .527 and .002 at 6 months; and .011, .001, .002 and .090 at 12 
months, respectively). 
Conclusion:  It can be concluded from this study that the amount of time it takes to be readmitted to the hospital 
or suffer death from acute exacerbation in patients suffering from COPD can be improved by adding non-
invasive ventilation to the oxygen therapy. 
Keywords: Chronic obstructive pulmonary disease (COPD), Non-invasive ventilation (NIV), Acute 
exacerbation of COPD. 
 
Introduction: 
Chronic obstructive pulmonary disease is a kind of lung disease which is obstructive in nature and is 
characterized by poor airflow and chronic breathing problems (1). Symptoms of COPD include cough with 
sputum and shortness of breath (2). It is a chronic progressive disease which gets worse with the passage of time. 
It gets so bad that it gets impossible to carry out everyday activities and the health related quality of life worsens 
with time (3). Chronic obstructive lung disease can be either of two conditions; chronic bronchitis and 
emphysema. A person is said to have chronic bronchitis if he has productive cough for at least three months each 
year for two years. The most common cause of COPD is tobacco smoking. Air pollution and genetics are minor 
factors. Inflammatory response to the irritants results in breakdown of lung tissue and narrowing of lung airways 
(4)
. Lung function tests are used to diagnose COPD. It can be differentiated from asthma as airway obstruction in 
asthma is intermittent and reversible and it gets better with the use of bronchodilators (5). According to an 
estimate, it affected about 174.5 million of global population in 2015 (6). It is the third leading cause of death 
worldwide (7). Acute exacerbation of COPD can be defined as increased cough in someone suffering from 
COPD, increased sputum production and change of color of sputum from clear to yellow or green (8). Signs of 
acute exacerbation may include sweating, fast breathing, confusion and combative behavior. 
The best prevention for COPD is to reduce the exposure from risk factors like smoking and air pollution. 
Treatment can slow down the progression of disease but there is no definite cure. Treatments include respiratory 
rehabilitation, vaccination, inhaled steroids and bronchodilators, long term oxygen therapy and lung 
transplantation (9). One treatment option for COPD is to do an oxygen therapy while other option is to add non 
invasive ventilation to this oxygen therapy. In this randomized controlled trial, we hypothesized that the time to 
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death or readmission in patients suffering from acute exacerbation of COPD will be prolonged by adding non-
invasive ventilation to simple oxygen therapy. 
Materials and Method:  
This controlled trial was conducted at department of pulmonology in Nishtar Hospital Multan over a period of 
two years. The number of patients was 194 which were divided into two groups of 100 and 94. Ethical approval 
regarding this study was taken from the hospital ethics committee. The study which was taken as a reference for 
this trial was done by Patrick B. et al (10). There were 100 patients who were given just oxygen therapy at home. 
Average flow rate of oxygen for them was 1.0 L/min. The number of patients who were given oxygen therapy 
combined with non-invasive ventilation was 94. The ventilator settings for inspiration were 24 cm H2O of air 
pressure which was positive, 4 cmH2O airway pressure, and backup rate of 14 breaths per minute. The non 
invasive ventilation was applied according to preference of patients by using nasal or total face masks. To 
increase the oxygen level to 60 mmHg, oxygen therapy was started at the minimum flow rate in both groups. The 
patients who were on oxygen therapy alone were instructed to undergo at least 15 hours of oxygen therapy daily. 
For the patients of other group, a minimum of 6 hours nightly use of ventilator was instructed. The patients were 
on optimized COPD management which included long acting beta agonists, antimuscarinics, and steroids. They 
were also educated on COPD self-management. 
 The patients who were included in the study were bound to have hypercapnia, hypoxemia and slightly acidic 
arterial pH while inspiring room air. The patients, who required invasive ventilation and intubation, were 
currently on home mechanical ventilation, showed cognitive impairment, had coronary artery disease were 
excluded from the study. The primary outcome of the study was the amount of time it takes to be readmitted to 
the hospital or suffer death after 12 months of randomization. Secondary outcomes included mortality due to all 
causes, frequency of exacerbations, change in arterial concentration of CO2 and O2 while inspiring room air, 
breathlessness, and health related quality of life. Hospital readmission and exacerbation data was collected at 
each follow up visits at 6 weeks, 3 months, 6 months and 12 months. 
The data was presented as mean or median as appropriate. All the analyses were assessed for superiority. The 
analysis was done according to intention-to-treat principle. Two-sided significance level of 0.05 was concluded. 
All the data was collected by the researcher himself on a preformed Performa. Data was analyzed using the 
software SPSS v.23.  
Results:  
 
Ninety four patients were put on oxygen therapy with non-invasive ventilation and 100 patients were put on just 
oxygen therapy. Both the groups were comparable in all baseline variables i.e. age, BMI, gender distribution, 
COPD related hospital readmissions, smoking duration, neck and waist circumference, FEV1, FVC, FEV1/FVC 
ratio, PaO2, PaCO2, arterial pH, Medical Research Council Dyspnea Score, Severe Respiratory Insufficiency 
Questionnaire summary score and St. George Respiratory Questionnaire summary score, except apnea hypopnea 
index which was statistically different between the groups (p=.001). Table-I 
After one year follow up, there was significant improvement in PaCO2, PaO2, St. George Respiratory 
Questionnaire summary score and Severe Respiratory Insufficiency Questionnaire summary score at most of the 
occasions (p-value <0.001 for all at 3 months; .060, .013, .527 and .002 at 6 months; and .011, .001, .002 and 
.090 at 12 months, respectively). Table-II and Table-III 
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Table-I 
Baseline variables 
Variable HO +NIV 
(N=94) 
HO Alone 
(n=100) 
P value Total 
(n=194) 
Age (years), mean ±S.D 63.20±5.30 62.43±4.56 .277 62.80±4.94 
BMI (kg/m2), mean ±S.D 31.32±4.33  31.24±4.34 .899 31.28±4.32 
Gender, M/F 68/26 66/34 .340 134/60 
Prior use of O2 therapy, n (%) 60 (63.8) 58 (58) .406 118 (60.8) 
≥3 COPD related readmissions, n (%) 71 (75.5) 66 (66) .145 137 (70.6) 
Smoking history (pack years), median (IQR) 38 (36-43) 38 (35-41) .251 38 (35.75-42) 
Apnea Hypopnea index, median (IQR) 3.5 (2.2-4.7) 2.7 (1.9-3.65) .001 2.85 (1.9-4.1) 
Neck circumference (cm), median (IQR) 37 (33-41) 37 (36-39) .075 37 (35-39.5) 
Waist circumference (cm), median (IQR) 94 (85-96) 94 (88.25-96) .094 94 (87-96) 
FEV1 (Liter), mean ±S.D .65±.29 .72±.25 .081 .68±.27 
FEV1 %Predicted, mean ±S.D 26.62±8.07 28.60±7.18 .073 27.58±7.70 
FVC (Liter), mean ±S.D 1.89±.44 1.85±.49 .606 1.86±.47 
FVC %Predicted, mean ±S.D 60.39±14.37 58.86±12.05 .427 59.49±13.25 
FEV1/FVC, mean ±S.D .36±.12 .35±.12 .757 .36±.12 
PaO2 at room air breathing (mmHg), mean ±S.D 50.25±7.40 50.19±6.67 .955 50.21±6.99 
PaCO2 at room air breathing (mmHg), mean ±S.D 58.84±8.06 60.59±8.18 .136 59.74±8.13 
Arterial pH at room air breathing, mean ±S.D 7.40±.12 7.39±.13 .576 7.39±.12 
St. George Respiratory Questionnaire summary score, 
median (IQR) 
71 (65-79) 74 (68-79) .561 72.5 (65-79) 
Severe Respiratory Insufficiency Questionnaire summary 
score, median (IQR) 
48 (39-58) 51 (41.5-60.5) .104 50 (41-59) 
Medical Research Council Dyspnea Score, median (IQR) 4 (3-5.25) 4.5(3.25-5.75) .973 4 (3-5.25) 
BMI=body mass index; COPD=chronic obstructive pulmonary disease; FEV1=forced expiratory volume of air in 
first second; FVC=forced vital capacity 
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Table-II 
Daytime Gas Exchange 
 
Factor 
 
Visit 
Number of Patients Median (IQR)  
P value HO+NIV HO Alone HO+NIV HO Alone 
PaCO2 Baseline 94 100 59 (53-65) 60 (54-68) .148 
3rd month 80 83 51 (47-56) 59 (54-63) <.001 
6th month 69 71 51 (45-58) 54 (45-58) .060 
12th month 58 59 47 (45-51) 51 (45-54) .011 
PaO2 Baseline 94 100 49 (47-56) 49 (46-56) .623 
3rd month 80 83 59 (54-65) 48 (45-51) <.001 
6th month 69 71 58 (54-65) 56(51-59) .013 
12th month 58 59 63 (55-66) 56 (54-60) .001 
 
Table-III 
Health Related Quality of Life 
 
Factor 
 
Visit 
Number of Patients Median (IQR)  
P value HO+NIV HO Alone HO+NIV HO Alone 
Severe Respiratory 
Insufficiency 
Questionnaire 
summary score 
Baseline 94 100 48 (39-58) 51 (41.5-60.5) .104 
3rd month 80 83 74 (65-79) 68 (63-74) <.001 
6th month 69 71 78 (64-81) 74 (68-81) .527 
12th month 58 59 81 (76-83) 74 (65-81) .002 
St. George 
Respiratory 
Questionnaire 
summary score 
Baseline 94 100 71 (65-79) 74 (68-79) .561 
3rd month 80 83 62 (58-65) 71 (68-78) <.001 
6th month 69 71 62 (56-65) 54 (59-71) .002 
12th month 58 59 55 (48.5-58.3) 58 (55-62) .090 
St. George Respiratory Questionnaire summary score (100=worst, 0=best); Severe Respiratory Insufficiency 
Questionnaire summary score (100=best, 0=worst).  (Note: N=194, student t-test for continuous data, chi-square 
for percentages, Mann-Whitney U test for median (IQR)) 
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Discussion:  
In this randomized trial, an improvement was observed after adding non-invasive ventilation to oxygen therapy 
after an acute exacerbation of COPD in time to fatality or readmission.  
A lot of studies support the results of our study. A reduction in need for endotracheal intubation can be observed 
in COPD patients treated with non invasive ventilation (11). Addition of non-invasive ventilation with positive 
pressure decreases the trend to retention of carbon dioxide and improves quality of life and dyspnoea (12). Non 
invasive positive pressure ventilation improves parameters like lung function, gas exchange and breathing 
pattern (13). When non invasive ventilation is targeted to reduce hypercapnia, it improves the survival of patients 
with hypercapnic stable COPD (14) where long term ventilation provides a better ventilation-perfusion match (15). 
The principle mechanisms by which non invasive ventilation improves gas exchange in patients with COPD are 
decreased gas trapping and increased sensitivity to CO2 (16). In high intensity non invasive ventilation, the 
component which plays a therapeutic role in the management of COPD is high pressure (17).  
There were some studies which contradict the results of our study. These studies suggest that addition of home 
non-invasive ventilation did not improve the duration of hospital readmission or time to death (18). One trial 
concluded that the risk of life threatening events in patients with COPD increases with the addition of non-
invasive ventilation (19). A study also concluded that while the addition of non invasive ventilation to oxygen 
therapy increases the survival rate, it worsens the quality of life (20).  
 
Conclusion:  
It can be concluded from this study that the amount of time it takes to be readmitted to the hospital or suffer 
death from acute exacerbation in patients suffering from COPD can be improved by adding non-invasive 
ventilation to the oxygen therapy. 
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